BACKGROUND AND OBJECTIVES: Regional cerebral atrophy occurs in carriers of the Huntington's disease (HD) gene mutation before clinical diagnosis is possible. The current inability to reliably measure progression of pathology in this preclinical phase impedes development of therapies to delay clinical onset. We hypothesised that longitudinal statistical imaging would detect progression of structural pathology in preclinical carriers of the HD gene mutation, in the absence of measurable clinical change. METHODS: Thirty subjects (17 preclinical mutation positive, 13 mutation negative) underwent serial clinical and magnetic resonance imaging (MRI) assessments over an interval of 2 years. Statistically significant changes in regional grey and white matter volume on MRI were analysed using tensor based morphometry (TBM). This technique derives a voxel-wise estimation of regional tissue volume change from the deformation field required to warp a subject's early to late T1 images. RESULTS: Over 2 years, there was progressive regional grey matter atrophy in mutation-positive relative to negative subjects, without significant clinical progression of disease. Significant grey matter volume loss was limited to bilateral putamen and globus pallidus externa (GPe), left caudate nucleus, and left ventral midbrain in the region of the substantia nigra. CONCLUSIONS: While these results are consistent with previous cross sectional pathologic and morphometric studies, significant progression of atrophy in HD before the onset of significant clinical decline is now demonstrable with longitudinal statistical imaging. Such measures could be used to assess the efficacy of potential disease modifying drugs in slowing the progression of pathology before confirmed clinical onset of HD.
BACKGROUND AND OBJECTIVES: Regional cerebral atrophy occurs in carriers of the Huntington's disease (HD) gene mutation before clinical diagnosis is possible. The current inability to reliably measure progression of pathology in this preclinical phase impedes development of therapies to delay clinical onset. We hypothesised that longitudinal statistical imaging would detect progression of structural pathology in preclinical carriers of the HD gene mutation, in the absence of measurable clinical change. METHODS: Thirty subjects (17 preclinical mutation positive, 13 mutation negative) underwent serial clinical and magnetic resonance imaging (MRI) assessments over an interval of 2 years. Statistically significant changes in regional grey and white matter volume on MRI were analysed using tensor based morphometry (TBM). This technique derives a voxel-wise estimation of regional tissue volume change from the deformation field required to warp a subject's early to late T1 images. RESULTS: Over 2 years, there was progressive regional grey matter atrophy in mutation-positive relative to negative subjects, without significant clinical progression of disease. Significant grey matter volume loss was limited to bilateral putamen and globus pallidus externa (GPe), left caudate nucleus, and left ventral midbrain in the region of the substantia nigra. CONCLUSIONS: While these results are consistent with previous cross sectional pathologic and morphometric studies, significant progression of atrophy in HD before the onset of significant clinical decline is now demonstrable with longitudinal statistical imaging. Such measures could be used to assess the efficacy of potential disease modifying drugs in slowing the progression of pathology before confirmed clinical onset of HD.
Authors: R L Albin; A Reiner; K D Anderson; L S Dure; B Handelin; R Balfour; W O Whetsell; J B Penney; A B Young Journal: Ann Neurol Date: 1992-04 Impact factor: 10.422
Authors: J P Vonsattel; R H Myers; T J Stevens; R J Ferrante; E D Bird; E P Richardson Journal: J Neuropathol Exp Neurol Date: 1985-11 Impact factor: 3.685
Authors: S T Grafton; J C Mazziotta; J J Pahl; P St George-Hyslop; J L Haines; J Gusella; J M Hoffman; L R Baxter; M E Phelps Journal: Arch Neurol Date: 1992-11
Authors: D S Adnan Majid; Adam R Aron; Wesley Thompson; Sarah Sheldon; Samar Hamza; Diederick Stoffers; Dominic Holland; Jody Goldstein; Jody Corey-Bloom; Anders M Dale Journal: Mov Disord Date: 2011-09-19 Impact factor: 10.338
Authors: Siamak Ardekani; Robert G Weiss; Albert C Lardo; Michael I Miller; Raimond L Winslow; Laurent Younes Journal: Proc IEEE Int Symp Biomed Imaging Date: 2009-06
Authors: Simona M Brambati; Natasha C Renda; Katherine P Rankin; Howard J Rosen; William W Seeley; John Ashburner; Michael W Weiner; Bruce L Miller; Maria Luisa Gorno-Tempini Journal: Neuroimage Date: 2007-02-04 Impact factor: 6.556
Authors: Dezso Nemeth; Cristina D Dye; Tamás Sefcsik; Karolina Janacsek; Zsolt Turi; Zsuzsa Londe; Péter Klivenyi; Zsigmond Tamás Kincses; Nikoletta Szabó; László Vecsei; Michael T Ullman Journal: Brain Lang Date: 2012-04-24 Impact factor: 2.381
Authors: S M Brambati; K P Rankin; J Narvid; W W Seeley; D Dean; H J Rosen; B L Miller; J Ashburner; M L Gorno-Tempini Journal: Neurobiol Aging Date: 2007-07-02 Impact factor: 4.673
Authors: H Diana Rosas; David H Salat; Stephanie Y Lee; Alexandra K Zaleta; Nathanael Hevelone; Steven M Hersch Journal: Ann N Y Acad Sci Date: 2008-12 Impact factor: 5.691
Authors: Jorge Jovicich; Silvester Czanner; Xiao Han; David Salat; Andre van der Kouwe; Brian Quinn; Jenni Pacheco; Marilyn Albert; Ronald Killiany; Deborah Blacker; Paul Maguire; Diana Rosas; Nikos Makris; Randy Gollub; Anders Dale; Bradford C Dickerson; Bruce Fischl Journal: Neuroimage Date: 2009-02-20 Impact factor: 6.556